4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT): 25 pipeline candidates · 2 upcoming catalysts · ~17 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.7 months
D/E 0.14 · 30% dilution
Lead: Phase 3
25 candidates
2 upcoming, next in ~12d
0 buys · 5 sells (180d)
A transparent, data-derived signal for 4D Molecular Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$482.0M
Cash
$72.5M
Quarterly Burn
$68.1M
Runway
16.7 mo
Revenue
$3.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (25 candidates)
| Drug | Phase |
|---|---|
| 150 ivt | Phase 3 |
| 4D-110 | Phase 1 |
| 4D-125 | Phase 2 |
| 4D-125 IVT Injection | Phase 3 |
| 4D-150 | Phase 3 |
| 4D-150 IVT | Phase 3 |
| 4D-175 | Preclinical |
| 4D-310 | Phase 1 |
| 4D-710 | Phase 2 |
| 4D-725 | Preclinical |
Showing 10 of 25 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
150
Total value held
$522.3M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 10,494,302 | $97.7M |
| ra capital management, l.p. | 5,049,779 | $47.0M |
| goldman sachs group inc | 4,205,438 | $39.2M |
| blackrock, inc. | 4,145,303 | $38.6M |
| novo holdings a/s | 3,650,737 | $34.0M |
| bvf inc/il | 2,879,289 | $26.8M |
| state street corp | 2,707,875 | $25.2M |
| vanguard capital management llc | 2,195,578 | $20.4M |
| armistice capital, llc | 2,000,000 | $18.6M |
| adage capital partners gp, l.l.c. | 1,605,156 | $14.9M |
Showing top 10 of 150 institutional holders of 4D Molecular Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in 4D Molecular Therapeutics, Inc.'s pipeline?
4D Molecular Therapeutics, Inc. (FDMT) has 25 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is 4D Molecular Therapeutics, Inc.'s lead drug candidate?
4D Molecular Therapeutics, Inc.'s most advanced tracked candidate is 150 ivt (Phase 3) for Neovascular Age-Related Macular Degeneration (nAMD).
What is 4D Molecular Therapeutics, Inc.'s next catalyst?
4D Molecular Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: 150" — expected June 30, 2026.
What is 4D Molecular Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, 4D Molecular Therapeutics, Inc. has approximately 16.7 months of cash runway.
What is 4D Molecular Therapeutics, Inc.'s market capitalization?
4D Molecular Therapeutics, Inc.'s market capitalization is approximately $482.0M.
Get the full picture on 4D Molecular Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.